Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW

Regorafenib Tablets

Regorafenib is a novel oral multi-target kinase inhibitor that can comprehensively and continuously inhibit angiogenesis, inhibit tumor cell proliferation and tumor metastasis, and regulate the tumor immune microenvironment to exert an effective anti-immunosuppressive effect. It is mainly clinically applicable to the treatment of the following diseases:
Metastatic colorectal cancer: patients who have previously received chemotherapy based on oxaliplatin, irinotecan, and fluorouracil, and patients who have previously received or are not suitable for anti-epidermal growth factor receptor (EGFR) therapy (RAS wild type) and anti-vascular endothelial growth factor (VEGF) therapy.
Gastrointestinal stromal tumors (GIST): patients with metastatic GIST who have previously received sunitinib malate or imatinib mesylate or locally advanced GIST that cannot be surgically removed.


Featured products

Laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor.